BoYen Therapeutics, Inc. (7891)

Overview

BoYen Therapeutics, Inc. is a biotechnology company based in Taiwan, established in 2010. The company is dedicated to the discovery, development, and clinical advancement of innovative small molecule drugs, focusing on meeting unmet medical needs in various therapeutic areas. Situated in Taipei, BoYen Therapeutics addresses critical challenges in neoplasms, hemic and lymphatic diseases, immune system disorders, nervous system diseases, and endocrinology through a proprietary drug pipeline.

Significant milestones achieved by the company include obtaining U.S. FDA orphan drug designation and receiving invitations for Investigational New Drug (IND) submissions for candidate BY-101. Additionally, the company has secured patents for anti-cancer prodrugs with the USPTO and EPO. Recognized as a Biotechnology New Drug Company by Taiwan's Ministry of Economic Affairs, BoYen Therapeutics plays a crucial role in advancing groundbreaking therapies toward global markets, with a strong focus on oncology and neurology.

Products and Services

• BY-102 - Currently in Phase 1 clinical trials, BY-102 is being developed as a treatment for multiple sclerosis. This novel drug aims to modify disease progression and enhance the quality of life for patients suffering from this serious neurological condition.
• BY-103 - At the preclinical stage, BY-103 is targeting hematologic neoplasms. This product represents the company’s commitment to developing therapies that specifically address blood cancers and improve therapeutic outcomes for patients.
• BYT-3156 - Another preclinical candidate, BYT-3156 is focused on targeting colonic cancer. The development of this drug emphasizes BoYen's dedication to tackling oncological challenges, with an aim to offer effective treatment alternatives for those affected by colorectal malignancies.